{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:07:16Z","timestamp":1760854036109,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["113657 09-53"],"award-info":[{"award-number":["113657 09-53"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["113657 09-53"],"award-info":[{"award-number":["113657 09-53"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00280-018-3624-6","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T04:25:24Z","timestamp":1529900724000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-9440","authenticated-orcid":false,"given":"John P.","family":"Fruehauf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"El-Masry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Osann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basmina","family":"Parmakhtiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Jakowatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"3624_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2017. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3624_CR2","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622\u20133634","journal-title":"J Clin Oncol"},{"key":"3624_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1159\/000448904","volume":"39","author":"MV Heppt","year":"2016","unstructured":"Heppt MV, Dietrich C, Graf SA, Ruzicka T, Tietze JK, Berking C (2016) The systemic management of advanced melanoma in 2016. Oncol Res Treat 39:635\u2013642","journal-title":"Oncol Res Treat"},{"issue":"8","key":"3624_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871\u2013878","journal-title":"J Clin Oncol"},{"key":"3624_CR5","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1200\/jco.2016.34.7_suppl.66","volume":"34","author":"K Flaherty","year":"2016","unstructured":"Flaherty K, Davies MA, Grob JJet al (2016) Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma. J Clin Oncol 34:9502\u20139502 (suppl; abstr 9502)","journal-title":"J Clin Oncol"},{"key":"3624_CR6","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867\u20131876","journal-title":"N Engl J Med"},{"key":"3624_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"3624_CR8","first-page":"JCO-2014","volume":"9","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal Clin Oncol 9:JCO-2014","journal-title":"Journal Clin Oncol"},{"key":"3624_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/jclinpath-2015-203482","volume":"69","author":"G Jour","year":"2016","unstructured":"Jour G, Ivan D, Aung PP (2016) Angiogenesis in melanoma: an update with a focus on current targeted therapies. J Clin Pathol 69:472\u2013483","journal-title":"J Clin Pathol"},{"key":"3624_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1525-1500.1998.0oa18.x","volume":"22","author":"SW Grant","year":"1998","unstructured":"Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP (1998) Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 22:185\u201394","journal-title":"Cancer Detect Prev"},{"key":"3624_CR11","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/cncr.23076","volume":"110","author":"JG Einspahr","year":"2007","unstructured":"Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS (2007) Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 110:2519\u20132527","journal-title":"Cancer"},{"key":"3624_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577\u2013583","journal-title":"J Clin Oncol"},{"key":"3624_CR13","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/ijc.22531","volume":"120","author":"J Gille","year":"2007","unstructured":"Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ et al (2007) Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 120:1899\u20131908","journal-title":"Int J Cancer"},{"key":"3624_CR14","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-11-0534","volume":"17","author":"JP Fruehauf","year":"2011","unstructured":"Fruehauf JP, Lutzky J, McDermott DF, Brown CK, Meric J-B, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O (2011) Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, 3, in patients with metastatic melanoma. Clin Cancer Res 17:7462\u20137469","journal-title":"Clin Cancer Res"},{"key":"3624_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2011.34.6270","volume":"30","author":"KB Kim","year":"2012","unstructured":"Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O\u2019Day SJ (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30:34\u201341","journal-title":"J Clin Oncol"},{"issue":"15","key":"3624_CR16","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"PA Harris","year":"2008","unstructured":"Harris PA, Boloor A, Cheung M et al (2008) Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51(15):4632\u20134640","journal-title":"J Med Chem"},{"key":"3624_CR17","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220\u20134227","journal-title":"Clin Cancer Res"},{"key":"3624_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10456-013-9334-0","volume":"16","author":"G Bocci","year":"2013","unstructured":"Bocci G, Di Paolo A, Danesi R (2013) The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 16:481\u2013492","journal-title":"Angiogenesis"},{"key":"3624_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4143\/crt.2007.39.4.150","volume":"39","author":"RS Kerbel","year":"2007","unstructured":"Kerbel RS (2007) Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 39:150\u2013159","journal-title":"Cancer Res Treat"},{"key":"3624_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M (2010) Andr\u00e9 N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455\u2013465","journal-title":"Nat Rev Clin Oncol"},{"key":"3624_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"3624_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527\u20133427","journal-title":"J Clin Oncol"},{"key":"3624_CR23","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","volume":"24","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738\u20134745","journal-title":"J Clin Oncol"},{"key":"3624_CR24","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2005.01.1551","volume":"23","author":"R Kaufmann","year":"2005","unstructured":"Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T et al (2005) Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23:9001\u20139007","journal-title":"J Clin Oncol"},{"key":"3624_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105\u20132116","journal-title":"J Clin Oncol"},{"key":"3624_CR26","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823\u20132830","journal-title":"J Clin Oncol"},{"key":"3624_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"3624_CR28","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"issue":"suppl","key":"3624_CR29","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2016.34.15_suppl.9504","volume":"34","author":"J Schachter","year":"2016","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L (2016) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. J Clin Oncol 34(suppl):9504","journal-title":"J Clin Oncol"},{"key":"3624_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"issue":"4","key":"3624_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"key":"3624_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3624-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:46:09Z","timestamp":1568911569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3624-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3624"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3624-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"28 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Research support: Glaxo Smith Kline, Inc. and Novartis, Inc. JP Fruehauf has received financial support from Novartis for speaking at educational symposia and for developing slide decks for educational symposia. No other authors have conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The IND for this FDA approved trial is held by JP Fruehauf and UC Irvine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"This trial was carried out with the approval of the UC Irvine IRB and all patients were required to provided informed consent prior to their participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}